OAM
RVMD icon

Oxford Asset Management’s Revolution Medicines RVMD Stock Holding History

Oxford Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$384K Sell
2,050
-7,183
-78% -$1.05M 0.19% 151
2026
Q1 		$898K Buy
9,233
+4,345
+89% +$439K 0.36% 59
2025
Q4 		$389K Buy
+4,888
New +$321K 0.14% 244
2025
Q3 		– Sell
-15,197
Closed -$559K – 700
2025
Q2 		$559K Buy
15,197
+2,748
+22% +$106K 0.18% 181
2025
Q1 		$440K Sell
12,449
-4,238
-25% -$172K 0.2% 166
2024
Q4 		$730K Buy
+16,687
New +$842K 0.32% 85

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Oxford Asset Management's RVMD Position: Q2 2026 in Review

Oxford Asset Management reduced its Revolution Medicines (RVMD) stake by 78% in Q2 2026, selling an estimated $1.05M and leaving 2,050 shares worth $384K. The position accounts for 0.19% of the portfolio, ranked #151.

Oxford Asset Management first reported a position in RVMD in Q4 2024 and has held it in 6 quarters since. The position peaked at $898K in Q1 2026. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Oxford Asset Management held 2,050 shares of Revolution Medicines worth $384K as of Q2 2026.
  • Oxford Asset Management sold 7,183 Revolution Medicines shares in Q2 2026, an estimated $1.05M.
  • Revolution Medicines made up 0.19% of Oxford Asset Management's portfolio in Q2 2026, its #151 holding.
  • Oxford Asset Management first reported a position in Revolution Medicines in Q4 2024 and has held it in 6 quarters since.
  • Oxford Asset Management's Revolution Medicines position peaked at $898K in Q1 2026.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.